Saturday 17 October 2026
Export GH’s income statement to Excel — free account
Guardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024. In the quarter to June 2026, revenue grew 44.3%, EPS fell 12.5%, free cash flow fell 5.46% and total debt rose 34.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
158.29
7.59
−4.58%
Follow GH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
8.64 | 13.04 | 11.23 | 16.85 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(220.20) | (485.56) | (184.78) | (345.01) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
9.23 | 13.35 | 11.60 | 17.23 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(37.38) | (70.95) | (66.74) | (110.07) | |
EV/FCF |
(29.75) | (52.23) | (49.12) | (78.82) | |
Quick Ratio |
2.94 | 4.42 | 4.25 | 3.53 | |
Current Ratio |
3.50 | 4.84 | 4.68 | 4.03 | |
Net Debt/EBITDA |
(6.02) | (2.59) | (3.37) | (3.73) | |
Debt/Assets |
87.30% | 74.69% | 78.50% | 78.59% | |
Debt/Equity |
(3.14) | (15.14) | (8.30) | (6.74) | |
Asset Turnover |
0.64 | 0.56 | 0.66 | 0.73 | |
Operating CF/Net income |
0.38 | 0.21 | 0.59 | 0.48 | |
Capex/Depreciation |
(1.01) | (6.67) | (2.27) | (1.37) | |
Interest Coverage |
(104.97) | (102.38) | (90.09) | (95.93) | |
Research and Development Expense of Revenue |
33.92% | 34.94% | 30.18% | 28.82% | |
Selling, General and Administrative Expense of Revenue |
68.12% | 72.64% | 75.27% | 75.11% | |
Intangible Assets out of Total Assets |
0.01 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
16.14% | 15.36% | 15.78% | 17.23% | |
Graham Net Nets |
(0.10) | (0.05) | (0.06) | (0.04) | |
Graham Number |
14.32 | 7.68 | 10.26 | 11.48 | |
Earnings Yield |
(5.14%) | (3.24%) | (3.67%) | (2.33%) | |
Free Cash Flow Yield |
(3.59%) | (1.96%) | (2.10%) | (1.30%) | |
Revenue per Share |
2.12 | 2.24 | 2.30 | 2.52 | |
Operating CF per Share |
(0.28) | (0.21) | (0.50) | (0.43) | |
Capex per Share |
(0.08) | (0.22) | (0.04) | (0.09) | |
Free Cash Flow per Share |
(0.37) | (0.43) | (0.54) | (0.52) | |
Cash per Share |
4.65 | 9.58 | 8.40 | 7.93 | |
Shareholders Equity per Share |
(2.84) | (0.79) | (1.38) | (1.68) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.84) | (0.79) | (1.38) | (1.68) | |
Free Cash Flow |
(45.76) | (54.22) | (71.20) | (69.54) | |
Working Capital |
591.97 | 1,163.32 | 1,075.36 | 1,025.68 | |
Capital Expenditures |
(10.35) | (27.85) | (5.58) | (11.76) | |
Net Current Asset Value |
(802.37) | (646.92) | (728.86) | (770.52) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.10 | 0.02 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
102.03 | 124.05 | 126.42 | 137.25 | |
Average Payables |
17.81 | 46.50 | 62.40 | 69.16 | |
Average Inventory |
81.39 | 78.48 | 80.55 | 94.76 | |
Average Assets |
1,407.76 | 1,749.63 | 1,629.76 | 1,622.15 | |
Average Common Equity |
(207.28) | (119.48) | (215.93) | (264.17) |
Columns are period end dates